Indaptus Therapeutics Drops on Cash Runway Worries
Indaptus Therapeutics shares fell Tuesday, underperforming the biotech sector as traders returned after the U.S. holiday break and took a harder look at the cancer-immunotherapy name’s cash situation. The stock dropped 6.6% to $1.14 by early afternoon. It opened at $1.22 and fell to an intraday low of $1.115. Volume was near 52,700 shares, which is light. The stock usually trades in small bursts.